Drugs / ASCA101
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05547906 | Nov 2021 → Feb 2024 | neoplasm | MetaFines | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07168226 | May 2026 → Apr 2028 expected | hypoproteinemia, hypercatabolic | MetaFines | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASCA101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07168226 ↗ |
| Route | Intravenous | “IV infusion Twice a Week, 8 times per each Cycle” NCT05547906 ↗ |